Tuesday, December 18, 2012 10:32:24 AM
---------------------------------------------------------
(From the Committee's conclusions)
Draft Topics for Discussion
1. Discuss the efficacy data of Ampligen considering the following:
a) Karnofsky performance scale (KPS)
b) Exercise tolerance testing (ETT)
c) Protocol-driven analyses
d) Post-hoc analyses
2. Discuss the safety data for Ampligen.
3. Considering the totality of the data, is there substantial evidence of efficacy for Ampligen for the treatment of patients with chronic fatigue syndrome (CFS)?
a) If not, what further data should be obtained?
4. Has the safety of Ampligen been adequately assessed and characterized for the treatment of chronic fatigue syndrome (CFS)?
a) If yes, is the safety profile of Ampligen adequate for approval for the treatment of CFS?
b) If not, what further data should be obtained?
5. Do the efficacy and safety data provide substantial evidence to support approval of Ampligen for the treatment of chronic fatigue syndrome (CFS)?
a) If not, what further data should be obtained?
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM